
|Videos|August 17, 2021
Dr. Susan Slovin on treatment selection in metastatic castration-sensitive prostate cancer
Author(s)Urology Times staff
Susan F. Slovin, MD, PhD, discusses the plethora of available treatment options and factors affecting treatment selection for patients with metastatic castration-sensitive prostate cancer.
Advertisement
Susan F. Slovin, MD, PhD, medical oncologist, associate vice chair, Academic Administration, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses the plethora of available treatment options and factors affecting treatment selection for patients with metastatic castration-sensitive prostate cancer.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA provides guidance on development pathway for testosterone therapy for women
2
Pearls & Perspectives: Leadership and Prostate Cancer, with Mark L. Gonzalgo, MD, PhD, MBA
3
Treatment Selection in Advanced Prostate Cancer
4
Pedro Freitas, MD, on consolidative surgery vs prolonged systemic therapy in MIBC
5






